Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about SQZ Biotechnologies Company
SQZ Biotechnologies Company News
SQZ Biotechnologies Company Quantitative Score
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Biotechnologies Company Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
SQZ Biotechnologies Company Financials
Table Compare
Compare SQZ metrics with: | |||
|---|---|---|---|
Earnings & Growth | SQZ | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | SQZ | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | SQZ | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | SQZ | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
SQZ Biotechnologies Company Income
SQZ Biotechnologies Company Balance Sheet
SQZ Biotechnologies Company Cash Flow
SQZ Biotechnologies Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
SQZ Biotechnologies Company Executives
| Name | Role |
|---|---|
| Dr. Armon R. Sharei Ph.D. | Co-Founder, Pres, Chief Executive Officer, & Director |
| Dr. Howard Bernstein M.D., Ph.D. | Interim Chief Executive Officer & Director |
| Mr. Lawrence J. Knopf Esq. | Gen. Counsel |
| Mr. Lawrence J. Knopf | Gen. Counsel |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Armon R. Sharei Ph.D. | Co-Founder, Pres, Chief Executive Officer, & Director | 1987 | 762.31K | |
| Dr. Howard Bernstein M.D., Ph.D. | Interim Chief Executive Officer & Director | 1957 | 552.14K | |
| Mr. Lawrence J. Knopf Esq. | Gen. Counsel | Male | 1962 | 512.38K |
| Mr. Lawrence J. Knopf | Gen. Counsel | Male | 1962 | 478.04K |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer | 1963 | 476.27K |
SQZ Biotechnologies Company Insider Trades
| Date | 14 Jun |
| Name | VINK PATRICK V.J.J. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 39875 |
| Date | 14 Jun |
| Name | Srivastava Sapna |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 39875 |
| Date | 14 Jun |
| Name | SCHULMAN AMY W |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 39875 |
| Date | 14 Jun |
| Name | SCHEGERIN MARC |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 39875 |
| Date | 14 Jun |
| Name | Jensen Klavs F. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 39875 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Jun | VINK PATRICK V.J.J. | Director | Acquired | A-Award | 39875 |
| 14 Jun | Srivastava Sapna | Director | Acquired | A-Award | 39875 |
| 14 Jun | SCHULMAN AMY W | Director, 10 percent owner | Acquired | A-Award | 39875 |
| 14 Jun | SCHEGERIN MARC | Director | Acquired | A-Award | 39875 |
| 14 Jun | Jensen Klavs F. | Director | Acquired | A-Award | 39875 |